Eckert & Ziegler SE (LON:0NZY)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 660.58M -28.9% |
| Revenue (ttm) | 269.09M +4.4% |
| Net Income | 42.83M +35.7% |
| EPS | 0.68 +36.4% |
| Shares Out | n/a |
| PE Ratio | 15.42 |
| Forward PE | 14.75 |
| Dividend | 0.19 (1.80%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 1,121 |
| Open | 12.38 |
| Previous Close | 12.30 |
| Day's Range | 12.26 - 12.42 |
| 52-Week Range | 12.17 - 18.75 |
| Beta | 1.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Eckert & Ziegler SE
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu... [Read more]
Financial Performance
In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.
Financial numbers in EUR Financial StatementsNews
Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ...
Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license i...
Eckert & Ziegler SE Earnings Call Transcript: Q2 2026
First half 2026 saw stable revenues and 5% net income growth, with strong performance in medical and radiopharmaceuticals. Full-year guidance is maintained, expecting a stronger H2 driven by license payments and improved product mix. Cash remains strong and the company is nearly debt-free.
Eckert & Ziegler SE Quarterly report: Q2 2026
Eckert & Ziegler SE has published its Q2 2026 quarterly earnings report on August 13, 2026.
Eckert & Ziegler SE Slides: Q2 2026
Eckert & Ziegler SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Eckert & Ziegler SE Slides: FY 2026
Eckert & Ziegler SE has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 26, 2026.
Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY
Original-Research: Eckert & Ziegler SE - from NuWays AG 13.05.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible ...
Eckert & Ziegler SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 7% sales growth and strong medical segment performance, offsetting a slow start in the IP segment. Full-year guidance is reaffirmed, with robust cash reserves and a focus on organic growth and targeted M&A. Competitive and market conditions remain stable.
Eckert & Ziegler SE Quarterly report: Q1 2026
Eckert & Ziegler SE has published its Q1 2026 quarterly earnings report on May 12, 2026.
Eckert & Ziegler SE Slides: Q1 2026
Eckert & Ziegler SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Eckert & Ziegler SE Earnings Call Transcript: Q4 2025
Sales exceeded €300 million in 2025, driven by medical segment growth and global expansion, with EBIT margin at 25% and strong cash flow. 2026 guidance targets €320 million sales and €80 million EBIT adjusted, with continued CapEx and cautious outlook on license income and FX impacts.
Eckert & Ziegler SE Annual report: Q4 2025
Eckert & Ziegler SE has published its Q4 2025 annual report on March 26, 2026.
Eckert & Ziegler SE Slides: Q4 2025
Eckert & Ziegler SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
Eckert & Ziegler SE Annual report: Q4 2025
Eckert & Ziegler SE has published its Q4 2025 annual report on March 26, 2026.
EQS-DD: Eckert & Ziegler SE: Dr. Gunnar Mann, Allocation of 12,545 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic ...
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.03.2026 / 10:17 CET/CEST The issuer is solely responsi...
EQS-DD: Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 62,541 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an ...
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.03.2026 / 10:04 CET/CEST The issuer is solely responsi...
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
EQS-Adhoc: Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025
EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Dividend payments Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025 06-March-2026 / 10:36 CET/CEST Disclosure of an inside information acc. to...
EQS-AFR: Eckert & Ziegler SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Eckert & Ziegler SE / Preliminary announcement on the disclosure of financial statements Eckert & Ziegler SE: Preliminary announcement of the publicatio...
EQS-AFR: Eckert & Ziegler SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Eckert & Ziegler SE / Preliminary announcement on the disclosure of financial statements Eckert & Ziegler SE: Preliminary announcement of the publicatio...
Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY • news
Eckert & Ziegler SE at JPMorgan Healthcare Conference Transcript
Eckert & Ziegler SE at JPMorgan Healthcare Conference Transcript
Eckert & Ziegler SE Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is expanding its global footprint and investing in capacity to meet rising demand for radioligand therapies, with strong growth in the medical segment and a robust financial position. Strategic partnerships, CDMO expansion, and selective M&A are key to future growth.